Email this article 
Sacubitril/valsartan as a component of therapy for chronic heart failure
- Authors: Danilov A.I.1, Evseev A.V.1, Evseeva M.A.1, Pavluchenkova O.V.1, Pereverzev V.A.2
-
Affiliations:
- Smolensk State Medical University
- Belarusian State Medical University
- Issue: Vol 20, No 4 (2022)
- Pages: 407-413
- Section: Reviews
- URL: https://journals.eco-vector.com/RCF/article/view/112537
- DOI: https://doi.org/10.17816/RCF204407-413
- ID: 112537
Cite item
Open Access
Access granted
Abstract
Chronic heart failure is in the vast majority of cases the outcome of many cardiovascular diseases. Despite significant achievements in the early diagnosis and treatment of cardiological pathology, the prevalence of chronic heart failure is steadily increasing, increasing the material costs of the healthcare system. Experts explain this aspect by the aging of the population of the developed countries of the world due to an increase in life expectancy. The presented review highlights the possibilities of using sacubitril/valsartan in clinical practice in order to inhibit the progression of chronic heart failure.
Full Text
About the authors
Andrey I. Danilov
Smolensk State Medical University
Email: dr.DanAndr@yandex.ru
ORCID iD: 0000-0002-6894-2462
SPIN-code: 7006-6887
Cand. Sci. (Med.), Assistant Professor
Russian Federation, SmolenskAndrey V. Evseev
Smolensk State Medical University
Author for correspondence.
Email: hypoxia@yandex.ru
ORCID iD: 0000-0001-7296-8502
SPIN-code: 9095-8712
Dr. Sci. (Med.), Professorand Head of the Deptment; Head of the Research Center
Russian Federation, SmolenskMarina A. Evseeva
Smolensk State Medical University
Email: marinaevseyeva@yandex.ru
ORCID iD: 0000-0003-4048-5260
SPIN-code: 6291-8901
Cand. Sci. (Med.), Assistant Professor
Russian Federation, SmolenskOlga V. Pavluchenkova
Smolensk State Medical University
Email: opavlyuchenkova@mail.ru
ORCID iD: 0000-0003-3359-0628
SPIN-code: 4826-7269
Cand. Sci. (Biol.), Assistant Professor
Russian Federation, SmolenskVladimir A. Pereverzev
Belarusian State Medical University
Email: pereverzev2010@mail.ru
SPIN-code: 8210-9406
Dr. Sci. (Med.), Professorand Head of the Department
Belarus, MinskReferences
- Rossiiskoe kardiologicheskoe obshchestvo. Khronicheskaya serdechnaya nedostatochnost’. Klinicheskie rekomendatsii 2020. Rossiiskii kardiologicheskii zhurnal. 2020;25(11). doi: 10.15829/1560-4071-2020-4083
- Danilov AI, Careva VM, Shpuntov MG, Drobot NV. Possibilities of Using aldosterone antagonists in patients with chronic heart failure. Trudnyj Pacient. 2019;17(5):6–8. (In Russ.)
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128
- McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242–247. doi: 10.1002/ejhf.250
- Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77.doi: 10.1042/CS20150469
- Napalkov DA, Zhilenko AV, Sulimov VA. Renin-angiotensin-aldosterone system and chronic heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2009;2(4):4–7. (In Russ.)
- Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34(12):886–893. doi: 10.1093/eurheartj/ehs262
- Nikiforov VS. Kombinirovannyi preparat sakubitril/valsartan — novyi etap v lechenii khronicheskoi serdechnoi nedostatochnosti. Medical Council. 2020;14:34–39. (In Russ.)
- Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci. 2017;13(5):1207–1216. doi: 10.5114/aoms.2017.68813
- Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639–653. doi: 10.1016/j.jacc.2016.04.060
- Jhund PS, McMurray JJV. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342–1347. doi: 10.1136/heartjnl-2014–306775
- Vilela-Martin JF. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther. 2016;10:1627–1639. doi: 10.2147/DDDT.S84782
- Webster CI, Burrell M, Olsson LL, et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer’s disease. PLoS One. 2014;9(8): e104001.doi: 10.1371/journal.pone.0104001
- McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077
